Wire flash
Fosun Pharma unit gets exclusive license from Amberstone for two T-MATE™-based products, total payments up to $236M
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 23, 2026, Fosun Pharma announced that its controlling subsidiary Shanghai Henlius Biotech has entered into a Collaboration and License Agreement with Amberstone. Under the deal, Henlius receives an exclusive worldwide license for all human uses to research, develop, manufacture, and commercialize two collaboration products targeting a specified target, based on Amberstone's T-MATE™ technology platform. Henlius will pay Amberstone up to $236.16 million in upfront fees, R&D expenses, and development and regulatory milestones, including an upfront payment of up to $4 million and up to $232.16 million in R&D and regulatory milestones tied to PCC, clinical studies, regulatory approvals, and launch progress. Additionally, Henlius may pay up to $652 million in tiered sales milestone payments based on annual net sales of the collaboration products in the licensed territory.
Source report
September 23 (Gelonghui) — Fosun Pharma announced today that its controlling subsidiary, Henlius, has entered into a Cooperation and License Agreement with Amberstone, dated September 23, 2026.
Key Terms of the Agreement
Under the agreement, Henlius has been granted an exclusive, worldwide license for all human-use indications to research, develop, manufacture, and commercialize two collaboration products targeting agreed-upon antigens, based on Amberstone's T-MATE™ technology platform.
Payment Structure
Upfront and Milestone Payments (up to $236.16 million):
- Upfront payment: Up to $4 million
- R&D, development, and regulatory milestones: Up to $232.16 million in total, payable upon achievement of specified milestones including PCC (Preclinical Candidate Confirmation), clinical studies, regulatory approvals, and commercialization progress
Sales Milestone Payments (up to $652 million):
- Henlius will make tiered sales milestone payments to Amberstone based on the achievement of annual net sales targets for the collaboration products in the licensed territory.
Source
格隆汇Eastern
Part of this Story
Fosun Pharma unit Henlius secures global license for two T-cell engager products from Amberstone